UnitedHealth Group Incorporated (NYSE:UNH) had its price objective lifted by Morgan Stanley from $210.00 to $215.00 in a report released on Thursday. They currently have an overweight rating on the healthcare conglomerate’s stock.
Several other analysts also recently issued reports on the stock. Cowen and Company reissued an outperform rating and issued a $220.00 price target (up previously from $175.00) on shares of UnitedHealth Group in a research report on Friday, August 11th. Zacks Investment Research raised shares of UnitedHealth Group from a hold rating to a buy rating and set a $215.00 price target for the company in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $205.00 price target (up previously from $203.00) on shares of UnitedHealth Group in a research report on Friday, July 21st. Sanford C. Bernstein reissued an outperform rating and issued a $210.00 price target (up previously from $190.00) on shares of UnitedHealth Group in a research report on Saturday, July 22nd. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $208.00 price target on shares of UnitedHealth Group in a research report on Friday, July 21st. One analyst has rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $203.41.
Shares of UnitedHealth Group (NYSE:UNH) traded down 0.98% during mid-day trading on Thursday, hitting $190.82. 2,858,486 shares of the stock were exchanged. UnitedHealth Group has a 12-month low of $132.39 and a 12-month high of $196.04. The stock has a market capitalization of $184.50 billion, a P/E ratio of 22.92 and a beta of 0.64. The stock’s 50 day moving average price is $190.34 and its 200-day moving average price is $175.66.
UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings results on Tuesday, July 18th. The healthcare conglomerate reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.08. UnitedHealth Group had a net margin of 4.32% and a return on equity of 21.52%. The business had revenue of $50.05 billion during the quarter, compared to the consensus estimate of $49.97 billion. During the same quarter last year, the firm posted $1.96 EPS. UnitedHealth Group’s revenue was up 7.7% compared to the same quarter last year. On average, equities research analysts expect that UnitedHealth Group will post $9.87 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “UnitedHealth Group Incorporated (UNH) Price Target Raised to $215.00 at Morgan Stanley” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2017/08/18/unitedhealth-group-incorporated-unh-price-target-raised-to-215-00-at-morgan-stanley.html.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 19th. Investors of record on Friday, September 8th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.57%. The ex-dividend date of this dividend is Thursday, September 7th. UnitedHealth Group’s dividend payout ratio is currently 35.13%.
In related news, Director Gail R. Wilensky sold 5,540 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $178.74, for a total value of $990,219.60. Following the sale, the director now directly owns 60,516 shares in the company, valued at approximately $10,816,629.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William C. Ballard, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $182.64, for a total value of $913,200.00. Following the completion of the sale, the director now owns 75,735 shares in the company, valued at $13,832,240.40. The disclosure for this sale can be found here. Insiders sold a total of 15,540 shares of company stock worth $2,873,320 over the last 90 days. 0.89% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. Regal Wealth Group Inc. boosted its stake in shares of UnitedHealth Group by 0.4% in the second quarter. Regal Wealth Group Inc. now owns 746 shares of the healthcare conglomerate’s stock worth $138,000 after buying an additional 3 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in shares of UnitedHealth Group by 0.4% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 1,097 shares of the healthcare conglomerate’s stock worth $180,000 after buying an additional 4 shares in the last quarter. Adirondack Trust Co. boosted its stake in shares of UnitedHealth Group by 0.5% in the first quarter. Adirondack Trust Co. now owns 990 shares of the healthcare conglomerate’s stock worth $162,000 after buying an additional 5 shares in the last quarter. RB Capital Management LLC boosted its stake in shares of UnitedHealth Group by 0.4% in the second quarter. RB Capital Management LLC now owns 1,732 shares of the healthcare conglomerate’s stock worth $321,000 after buying an additional 7 shares in the last quarter. Finally, Altfest L J & Co. Inc. boosted its stake in shares of UnitedHealth Group by 0.3% in the second quarter. Altfest L J & Co. Inc. now owns 2,963 shares of the healthcare conglomerate’s stock worth $549,000 after buying an additional 10 shares in the last quarter. Institutional investors and hedge funds own 86.21% of the company’s stock.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
